Phase 3Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
- Sponsor
- Verastem, Inc. (Industry)
- Enrolment
- 270 planned
- Conditions
- Low Grade Serous Ovarian Cancer
- Interventions
- avutometinib; Defactinib; Pegylated liposomal doxorubicin; Paclitaxel; Letrozole; Anastrozole
- Ages
- adults, older adults
- Registry
- NCT06072781
Full record on ClinicalTrials.gov
From the registry
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Primary outcomes
- Progression Free Survival (PFS) per blinded independent central review (BICR)
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered